$ACET
Adicet Bio, Inc. Stock $acet

$acet Overview Financials Valuation SEC Filings Company Website

2020 Form 10-K Financial Statement

#000156459021012664 Filed on March 12, 2021

Income Statement

Concept	2020	2019 Q4	2019
Revenue	$17.90M	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$22.76M	$3.330M	$11.82M
YoY Change	92.55%	65.67%	36.81%
% of Gross Profit
Research & Development	$34.33M	$26.11M	$23.69M
YoY Change	44.92%	500.23%	60.98%
% of Gross Profit
Depreciation & Amortization	$1.230M	$40.00K	$100.0K
YoY Change	1130.0%	100.0%	25.0%
% of Gross Profit
Operating Expenses	$57.09M	$29.44M	$85.46M
YoY Change	-33.19%	362.89%	269.22%
Operating Profit	-$39.19M	-$29.44M	-$85.46M
YoY Change	-54.14%	362.83%	115.23%
Interest Expense	$134.0K	$2.820M	$2.820M
YoY Change	-95.25%
% of Operating Profit
Other Income/Expense, Net	-$953.0K	-$2.270M	$2.331M
YoY Change	-140.88%	-460.32%	9.95%
Pretax Income	-$39.49M	-$28.89M	-$28.12M
YoY Change	40.45%	404.19%	184.38%
Income Tax	-$2.815M	$10.00K	$19.00K
% Of Pretax Income
Net Earnings	-$36.68M	-$28.89M	-$28.14M
YoY Change	30.35%	401.82%	202.59%
Net Earnings / Revenue	-204.91%
Basic Earnings Per Share
Diluted Earnings Per Share	-$5.011M	-$6.641M	-$16.89M
COMMON SHARES
Basic Shares Outstanding	7.320M	36.44M	2.148M
Diluted Shares Outstanding

Balance Sheet

Concept	2020	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$94.60M	$62.40M	$62.40M
YoY Change	51.6%	-42.22%	-42.22%
Cash & Equivalents	$84.30M	$10.61M	$10.60M
Short-Term Investments	$10.30M	$51.79M	$51.80M
Other Short-Term Assets	$3.000M	$179.0K	$900.0K
YoY Change	233.33%	1093.33%	-40.0%
Inventory
Prepaid Expenses		$615.0K
Receivables
Other Receivables
Total Short-Term Assets	$100.3M	$93.25M	$64.20M
YoY Change	56.23%	-14.86%	-41.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.90M	$2.121M	$2.100M
YoY Change	1133.33%	560.75%	600.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$10.60M	$10.60M
YoY Change	-100.0%
Other Assets	$6.400M	$410.0K	$4.700M
YoY Change	36.17%	310.0%	4600.0%
Total Long-Term Assets	$53.50M	-$11.67M	$17.40M
YoY Change	207.47%	-2980.49%	4250.0%
TOTAL ASSETS
Total Short-Term Assets	$100.3M	$93.25M	$64.20M
Total Long-Term Assets	$53.50M	-$11.67M	$17.40M
Total Assets	$153.8M	$81.59M	$81.60M
YoY Change	88.48%	-25.79%	-25.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.600M	$1.052M	$1.100M
YoY Change	45.45%	-64.8%	-63.33%
Accrued Expenses	$6.900M	$5.483M	$2.800M
YoY Change	146.43%	101.06%	3.7%
Deferred Revenue		$10.99M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$22.50M	$14.87M	$14.90M
YoY Change	51.01%	160.06%	161.4%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$21.40M	$15.00K	$13.00M
YoY Change	64.62%	-21.05%
Total Long-Term Liabilities	$21.40M	$15.00K	$13.00M
YoY Change	64.62%	-21.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.50M	$14.87M	$14.90M
Total Long-Term Liabilities	$21.40M	$15.00K	$13.00M
Total Liabilities	$44.00M	$27.87M	$27.90M
YoY Change	57.71%	385.96%	389.47%
SHAREHOLDERS EQUITY
Retained Earnings		-$69.65M
YoY Change		-2.45%
Common Stock		$9.262M
YoY Change		-94.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$109.8M	-$60.37M	$53.70M
YoY Change
Total Liabilities & Shareholders Equity	$153.8M	$81.59M	$81.60M
YoY Change	88.48%	-25.79%	-25.75%

Cashflow Statement

Concept	2020	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$36.68M	-$28.89M	-$28.14M
YoY Change	30.35%	401.82%	202.59%
Depreciation, Depletion And Amortization	$1.230M	$40.00K	$100.0K
YoY Change	1130.0%	100.0%	25.0%
Cash From Operating Activities	-$41.55M	-$25.64M	-$27.88M
YoY Change	49.03%	232.12%	53.37%
INVESTING ACTIVITIES
Capital Expenditures	$990.0K	-$30.00K	$1.070M
YoY Change	-7.48%	0.0%	22.15%
Acquisitions
YoY Change
Other Investing Activities	$116.2M	$36.00M	$44.40M
YoY Change	161.73%	-546.65%	-144.25%
Cash From Investing Activities	$115.2M	$35.97M	-$47.93M
YoY Change	-340.38%	-544.62%	198.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	303.0K	-10.00K	76.95M
YoY Change	-99.61%		596.59%
NET CHANGE
Cash From Operating Activities	-41.55M	-25.64M	-27.88M
Cash From Investing Activities	115.2M	35.97M	-47.93M
Cash From Financing Activities	303.0K	-10.00K	76.95M
Net Change In Cash	73.97M	10.32M	1.132M
YoY Change	6434.28%	-165.28%	-104.88%
FREE CASH FLOW
Cash From Operating Activities	-$41.55M	-$25.64M	-$27.88M
Capital Expenditures	$990.0K	-$30.00K	$1.070M
Free Cash Flow	-$42.54M	-$25.61M	-$28.95M
YoY Change	46.94%	233.03%	51.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	109827000
CY2020	us-gaap	Profit Loss ProfitLoss	-36678000
CY2020	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2014-11-30
CY2020	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000
CY2019	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y4M24D
CY2019	acet	Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm	P6Y7M20D
CY2020	acet	Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm	P5Y7M28D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M7D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M25D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M10D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M23D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M9D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y11M23D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1860646
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4527000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	56000
CY2020	us-gaap	Lease Cost LeaseCost	950000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	3168000
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10607000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	10284000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	51793000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5722000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1786000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	100336000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23066000
CY2020Q4	us-gaap	Goodwill Goodwill	20089000
CY2020Q4	us-gaap	Development In Process DevelopmentInProcess	1190000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4282000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	10588000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1837000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	410000
CY2020Q4	us-gaap	Assets Assets	153835000
CY2019Q4	us-gaap	Assets Assets	81587000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1552000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1052000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13980000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10993000
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5732000
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2820000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1215000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22479000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14865000
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10890000
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	234000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20424000
CY2019Q4	acet	Redeemable Convertible Preferred Stock Warrant Liability RedeemableConvertiblePreferredStockWarrantLiability	1881000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	980000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	125000
CY2020Q4	us-gaap	Liabilities Liabilities	44008000
CY2019Q4	us-gaap	Liabilities Liabilities	27870000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	140200938
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19677249
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19677249
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2155578
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2155578
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	216126000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	9258000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-106325000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-69647000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	24000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	23000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	109827000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-60366000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153835000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81587000
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	17903000
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	995000
CY2018	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	8181000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34334000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23691000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14717000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8692000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8428000
CY2018	us-gaap	Operating Expenses OperatingExpenses	23145000
CY2020	us-gaap	Interest Expense InterestExpense	134000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-953000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2331000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39493000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28119000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9888000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2815000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-589000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36678000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-28138000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-9299000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.01
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-13.15
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.78
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7319977
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2138973
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1946976
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	36000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000
CY2020	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	1000
CY2019	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	36000
CY2018	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-13000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36677000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28102000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9312000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-26948000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	221000
CY2018	acet	Stock Issued During Period Value Vesting Of Early Stock Option Exercised StockIssuedDuringPeriodValueVestingOfEarlyStockOptionExercised	44000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2479000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-9299000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-33516000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000
CY2019	acet	Stock Issued During Period Value Vesting Of Early Stock Option Exercised StockIssuedDuringPeriodValueVestingOfEarlyStockOptionExercised	47000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1175000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-28138000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	36000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-60366000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	460000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5263000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	114083000
CY2020	acet	Stock Exchanged During Period Value In Connection With Merger StockExchangedDuringPeriodValueInConnectionWithMerger	83516000
CY2020	acet	Stock Issued During Period Value Upon Accelerated Vesting Of Rsu With Merger StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger	626000
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	2922000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36678000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.258
CY2019	us-gaap	Profit Loss ProfitLoss	-28138000
CY2018	us-gaap	Profit Loss ProfitLoss	-9299000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1226000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1238000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1222000
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense	725000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5263000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1175000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	2479000
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	27000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-5000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	197000
CY2019	acet	Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And Trdf Liability ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability	2024000
CY2018	acet	Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And Trdf Liability ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability	4536000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	897000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-250000
CY2020	acet	Impairment Of In Process Research And Development ImpairmentOfInProcessResearchAndDevelopment	2300000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1900000
CY2020	acet	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts	134000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3233000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1405000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2825000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1260000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	88000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	302000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-814000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	527000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-282000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-7903000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-995000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3181000
CY2019	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-148000
CY2018	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-132000
CY2020	acet	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-859000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	787000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-360000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1324000
CY2020	acet	Increase Decrease In Deferred Tax Liability IncreaseDecreaseInDeferredTaxLiability	-242000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41552000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27882000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18180000
CY2020	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	64114000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5700000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	76078000
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	15182000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	57793000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	29099000
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	118000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	990000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1070000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	876000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47931000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16058000
CY2019	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	76915000
CY2018	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	10825000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	221000
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	157000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	303000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76945000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11046000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	73968000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1132000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23192000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14889000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13757000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36949000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88857000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14889000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13757000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84330000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10607000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9475000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4527000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4282000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4282000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88857000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14889000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13757000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	3000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	5109000
CY2020	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	664000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	115000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	48000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	61000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22367000
CY2020	acet	Issuance Of Redeemable Convertible Preferred Stock On Exercise Of Warrants With Loan Agreement IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement	144000
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	114083000
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	2922000
CY2020	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	84142000
CY2020	acet	Goodwill Measurement Period Adjustments GoodwillMeasurementPeriodAdjustments	650000
CY2019	acet	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	47000
CY2018	acet	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	44000
CY2018	acet	Exercise Of Redeemable Convertible Preferred Stock Tranche Liabilities ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities	902000
CY2019	acet	Termination Of Redeemable Convertible Preferred Stock Tranche Liability TerminationOfRedeemableConvertiblePreferredStockTrancheLiability	1143000
CY2019	acet	Settlement Of Trdf Liability SettlementOfTRDFLiability	88000
CY2020	acet	Entity Date Of Merger EntityDateOfMerger	2020-04-28
CY2020Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.25
CY2020Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-7
CY2020Q3	acet	Exchange Ratio ExchangeRatio	0.1240
CY2020Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.25
CY2020Q3	acet	Exchange Ratio ExchangeRatio	0.1240
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.52%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of the intangible assets acquired in business combinations, redeemable convertible preferred stock warrant liability, redeemable convertible preferred stock tranche liability, the Technion Research and Development Foundation liability (TRDF Liability), contingent consideration liability for contingent value right (CVR), deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company’s incremental borrowing rate. Actual results could differ from those estimates.</p>
CY2020	acet	Gain Loss On Change In Fair Value Of Contingent Consideration Liability GainLossOnChangeInFairValueOfContingentConsiderationLiability	1900000
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.52%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, and marketable debt securities. The Company’s cash and cash equivalents are held at two financial institutions in the U.S. and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents and marketable debt securities in money market funds, U.S. government securities, commercial paper, corporate bonds, and asset-backed securities. The Company limits its credit risk associated with cash equivalents and marketable debt securities by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents and marketable debt securities to date.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.52%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has one customer, Regeneron Pharmaceuticals, Inc. (Regeneron), which represents 100% of the Company’s total revenue during the years ended December 31, 2020, 2019 and 2018 (see Note 10).</p>
CY2020Q4	acet	Number Of Customer NumberOfCustomer	1
CY2020	acet	Customers Percentage Of Total Revenue CustomersPercentageOfTotalRevenue	1
CY2019	acet	Customers Percentage Of Total Revenue CustomersPercentageOfTotalRevenue	1
CY2018	acet	Customers Percentage Of Total Revenue CustomersPercentageOfTotalRevenue	1
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.277
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1400000
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1800000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23100000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21600000
CY2020	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	400000
CY2020Q3	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Percentage BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage	0.750
CY2020Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-7
CY2020	acet	Business Acquisitions Pro Forma Revenue1 BusinessAcquisitionsProFormaRevenue1	17903000
CY2019	acet	Business Acquisitions Pro Forma Revenue1 BusinessAcquisitionsProFormaRevenue1	995000
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-35757000
CY2019	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-113151000
CY2020	acet	Milestone Closing Liability MilestoneClosingLiability	6200000
CY2020	acet	Additional Closing Liability AdditionalClosingLiability	5000000.0
CY2020	acet	Increase Decrease In Estimated Fair Value Of Cvr Liability IncreaseDecreaseInEstimatedFairValueOfCvrLiability	1900000
CY2020Q4	acet	Estimated Fair Value Of Cvr Liability EstimatedFairValueOfCVRLiability	1000000.0
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	10260000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	24000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	10284000
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	62358000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	30000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	62381000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	10260000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	10284000
CY2020Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	10260000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	10284000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	10284000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	51793000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	10588000
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	10284000
CY2019Q4	us-gaap	Marketable Securities MarketableSecurities	62381000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1185000
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	615000
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1443000
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	57000
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2711000
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	722000
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	20000
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	213000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	363000
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	179000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5722000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1786000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7654000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5759000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4864000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3638000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2790000
CY2020	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	859000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22367000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23100000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21600000
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	0
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2121000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3833000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1359000
CY2020Q4	acet	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	1187000
CY2019Q4	acet	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	450000
CY2020Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	386000
CY2019Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	301000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	326000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	710000
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5732000
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2820000
CY2020Q2	us-gaap	Loans Receivable Basis Spread On Variable Rate LoansReceivableBasisSpreadOnVariableRate	0.0500
CY2020	us-gaap	Debt Instrument Maturity Date Range End1 DebtInstrumentMaturityDateRangeEnd1	2021-10-28
CY2020Q4	acet	Loan Amount Drawn LoanAmountDrawn	0
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	100000
CY2020	acet	Incremental Expense IncrementalExpense	0
CY2020Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	200000
CY2020	acet	Licence Agreement Cumulative Revenue Recognised LicenceAgreementCumulativeRevenueRecognised	17900000
CY2019	acet	Licence Agreement Cumulative Revenue Recognised LicenceAgreementCumulativeRevenueRecognised	1000000.0
CY2018	acet	Licence Agreement Cumulative Revenue Recognised LicenceAgreementCumulativeRevenueRecognised	8200000
CY2019Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2019Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	3500000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	700000
CY2018	us-gaap	Operating Lease Payments OperatingLeasePayments	500000
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0720
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	894000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	2505000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	2818000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	3429000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	3525000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	3624000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	13747000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	29648000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8009000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21639000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1215000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20424000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2721000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3518000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2942000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2798000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2882000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	16328000
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	31189000
CY2020	acet	Lawsuits Filed Against Company LawsuitsFiledAgainstCompany	7
CY2020Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	200000
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	99363444
CY2019Q4	acet	Temporary Equity Shares Issued And Outstanding TemporaryEquitySharesIssuedAndOutstanding	97166921
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	114083000
CY2019Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	128195000
CY2019Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	12048671
CY2020	acet	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	128260
CY2020	acet	Number Of Securities Converted To Warrants To Purchase Common Stock NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock	1683456
CY2020Q4	acet	Class Of Warrant Outstanding And Exercisable To Purchase Common Stock ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock	226191
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.3177
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	226191
CY2020	acet	Milestone Closing Liability MilestoneClosingLiability	6200000
CY2020	acet	Additional Closing Liability AdditionalClosingLiability	5000000.0
CY2019	acet	Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And Trdf Liabilities ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiabilities	2000000.0
CY2020Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2900000
CY2019Q4	acet	Class Of Warrant Outstanding And Exercisable To Purchase Preferred Shares ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares	1781387
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.4034
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.05
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5812000
CY2020	acet	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant As Part Of Merger ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger	2707144
CY2020	acet	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed As Part Of Merger ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger	81370
CY2020	acet	Share Based Compensation Arrangements By Share Based Payment Award Options Assumed As Part Of Merger In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice	8.39
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5672757
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	14834849
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	600000
CY2020	acet	Termination Agreement Month And Year TerminationAgreementMonthAndYear	2021-02
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	22574
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.75
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	38055
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	963435
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.02
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4977000
CY2018	acet	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized	837000
CY2018	acet	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted	210452
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	210452
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.26
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	123949
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.92
CY2018	acet	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled	153399
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	153399
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.25
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	818002
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	896539
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.04
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2436000
CY2019	acet	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized	814184
CY2019	acet	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted	1124430
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1124430
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.39
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	14791
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.12
CY2019	acet	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled	145380
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	145532
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.17
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	653136
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	654000
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	26000
CY2020	acet	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted	1914142
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2276645
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.14
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	210752
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.18
CY2020	acet	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled	293483
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	300964
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.04
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1739621
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3706945
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.90
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15126000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1219904
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.64
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11563000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3706945
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.90
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	15126000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2500000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.001
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5263000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1175000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2479000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36678000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28138000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9299000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7319977
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2148317
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2049680
CY2019	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	9344
CY2018	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	102704
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7319977
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2138973
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1946976
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.01
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-13.15
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.78
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3933136
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14130207
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6670510
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-2678000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	105000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-589000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	18000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-2573000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	19000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-589000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-242000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-242000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2815000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-589000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.005
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.001
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.061
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.038
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0.000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	-0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	-0.022
CY2020	acet	Effective Income Tax Rate Reconciliation Nol Carryback EffectiveIncomeTaxRateReconciliationNOLCarryback	0.067
CY2019	acet	Effective Income Tax Rate Reconciliation Nol Carryback EffectiveIncomeTaxRateReconciliationNOLCarryback	0.000
CY2018	acet	Effective Income Tax Rate Reconciliation Nol Carryback EffectiveIncomeTaxRateReconciliationNOLCarryback	0.000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.060
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.071
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5719000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.054
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	51796000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12510000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5233000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.200
CY2020	acet	Effective Income Tax Rate Reconciliation Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And Trdf Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability	-0.005
CY2020Q4	acet	Deferred Tax Operating Lease Right Of Use Asset Liability DeferredTaxOperatingLeaseRightOfUseAssetLiability	5686000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2857000
CY2019	acet	Effective Income Tax Rate Reconciliation Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And Trdf Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability	0.017
CY2018	acet	Effective Income Tax Rate Reconciliation Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And Trdf Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability	0.087
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5125000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1750000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	509000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	274000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1195000
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	609000
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	804000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	446000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	431000
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	26000
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	26000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63964000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19819000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11893000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57715000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19815000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11739000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6249000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	154000
CY2019Q4	acet	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	4000
CY2018Q4	acet	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	154000
CY2020Q4	acet	Deferred Tax Basis Difference Iprd DeferredTaxBasisDifferenceIPRD	-313000
CY2020Q4	acet	Deferred Tax Operating Lease Right Of Use Asset DeferredTaxOperatingLeaseRightOfUseAsset	-6061000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	125000
CY2020	acet	Deferred Tax Assets Valuation Allowance Increase DeferredTaxAssetsValuationAllowanceIncrease	37900
CY2019	acet	Deferred Tax Assets Valuation Allowance Increase DeferredTaxAssetsValuationAllowanceIncrease	8100
CY2020	acet	Ownership Change Plan Description OwnershipChangePlanDescription	In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	797000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	797000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	866000
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	69000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	797000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	797000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	797000
CY2020	acet	Company Contribution To Plan With Respect To Employees Contribution CompanyContributionToPlanWithRespectToEmployeesContribution	0

Files In Submission

Name	View Source	Status
0001564590-21-012664-index-headers.html	Edgar Link	pending
0001564590-21-012664-index.html	Edgar Link	pending
0001564590-21-012664.txt	Edgar Link	pending
0001564590-21-012664-xbrl.zip	Edgar Link	pending
acet-10k_20201231.htm	Edgar Link	pending
acet-10k_20201231_htm.xml	Edgar Link	completed
acet-20201231.xsd	Edgar Link	pending
acet-20201231_cal.xml	Edgar Link	unprocessable
acet-20201231_def.xml	Edgar Link	unprocessable
acet-20201231_lab.xml	Edgar Link	unprocessable
acet-20201231_pre.xml	Edgar Link	unprocessable
acet-ex1020_337.htm	Edgar Link	pending
acet-ex211_341.htm	Edgar Link	pending
acet-ex231_887.htm	Edgar Link	pending
acet-ex232_966.htm	Edgar Link	pending
acet-ex311_340.htm	Edgar Link	pending
acet-ex312_338.htm	Edgar Link	pending
acet-ex321_339.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gvts5uzh2ult000001.jpg	Edgar Link	pending
gvts5uzh2ult000002.jpg	Edgar Link	pending
gvts5uzh2ult000003.jpg	Edgar Link	pending
gvts5uzh2ult000004.jpg	Edgar Link	pending
gvts5uzh2ult000005.jpg	Edgar Link	pending
gvts5uzh2ult000006.jpg	Edgar Link	pending
gvts5uzh2ult000007.jpg	Edgar Link	pending
gvts5uzh2ult000008.jpg	Edgar Link	pending
gvts5uzh2ult000009.jpg	Edgar Link	pending
gvts5uzh2ult000010.jpg	Edgar Link	pending
gvts5uzh2ult000011.jpg	Edgar Link	pending
gvts5uzh2ult000012.jpg	Edgar Link	pending
gvts5uzh2ult000013.jpg	Edgar Link	pending
gvts5uzh2ult000014.jpg	Edgar Link	pending
gvts5uzh2ult000015.jpg	Edgar Link	pending
gvts5uzh2ult000016.jpg	Edgar Link	pending
gvts5uzh2ult000017.jpg	Edgar Link	pending
gvts5uzh2ult000018.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACET
Adicet Bio, Inc. Stock $acet

2020 Form 10-K Financial Statement

#000156459021012664 Filed on March 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACET Adicet Bio, Inc. Stock $acet

2020 Form 10-K Financial Statement

#000156459021012664 Filed on March 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACET
Adicet Bio, Inc. Stock $acet